{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:50:38Z","timestamp":1794441038901,"version":"4.9.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370063, 82170069, 82241012, 82120108001, 81970057, 82170065, 82000045, 82270052"],"award-info":[{"award-number":["82370063, 82170069, 82241012, 82120108001, 81970057, 82170065, 82000045, 82270052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370063, 82170069, 82241012, 82120108001, 81970057, 82170065, 82000045, 82270052"],"award-info":[{"award-number":["82370063, 82170069, 82241012, 82120108001, 81970057, 82170065, 82000045, 82270052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Research and Development Program of China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-024-02916-w","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T09:02:30Z","timestamp":1722330150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nephrectomy and high-salt diet inducing pulmonary hypertension and kidney damage by increasing Ang II concentration in rats"],"prefix":"10.1186","volume":"25","author":[{"given":"Qian","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dansha","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhui","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanjie","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huazhuo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenju","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason X.-J.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-256X","authenticated-orcid":false,"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7011-7250","authenticated-orcid":false,"given":"Yuqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"2916_CR1","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.66.S1.3","author":"AL Ammirati","year":"2020","unstructured":"Ammirati AL. Chronic kidney disease. Revista da Associacao Med Brasileira. 2020. https:\/\/doi.org\/10.1590\/1806-9282.66.S1.3.","journal-title":"Revista da Associacao Med Brasileira"},{"key":"2916_CR2","doi-asserted-by":"publisher","first-page":"105905","DOI":"10.1016\/j.rmed.2020.105905","volume":"164","author":"J Devasahayam","year":"2020","unstructured":"Devasahayam J, Oliver T, Joseph V, Nambiar S, Gunasekaran K. Pulmonary hypertension in end-stage renal disease. Respir Med. 2020;164:105905. https:\/\/doi.org\/10.1016\/j.rmed.2020.105905.","journal-title":"Respir Med"},{"key":"2916_CR3","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1053\/j.ajkd.2019.12.005","volume":"75","author":"CP Walther","year":"2020","unstructured":"Walther CP, Nambi V, Hanania NA, Navaneethan SD. Diagnosis and management of pulmonary hypertension in patients with CKD. Am J Kidney Dis Official J Nat Kidney Found. 2020;75:935\u201345. https:\/\/doi.org\/10.1053\/j.ajkd.2019.12.005.","journal-title":"Am J Kidney Dis Official J Nat Kidney Found"},{"key":"2916_CR4","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s11255-020-02589-6","volume":"52","author":"X Zhang","year":"2020","unstructured":"Zhang X, et al. Prognostic value of pulmonary hypertension in pre-dialysis chronic kidney disease patients. Int Urol Nephrol. 2020;52:2329\u201336. https:\/\/doi.org\/10.1007\/s11255-020-02589-6.","journal-title":"Int Urol Nephrol"},{"key":"2916_CR5","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.116.003940","author":"S Selvaraj","year":"2017","unstructured":"Selvaraj S, et al. Pulmonary hypertension is associated with a higher risk of heart failure hospitalization and mortality in patients with chronic kidney disease: the jackson heart study. Circ Heart Failure. 2017. https:\/\/doi.org\/10.1161\/circheartfailure.116.003940.","journal-title":"Circ Heart Failure"},{"key":"2916_CR6","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s11255-018-1853-6","volume":"50","author":"W Shang","year":"2018","unstructured":"Shang W, et al. Prevalence of pulmonary hypertension in patients with chronic kidney disease without dialysis: a meta-analysis. Int Urol Nephrol. 2018;50:1497\u2013504. https:\/\/doi.org\/10.1007\/s11255-018-1853-6.","journal-title":"Int Urol Nephrol"},{"key":"2916_CR7","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","volume":"387","author":"S Bhandari","year":"2022","unstructured":"Bhandari S, et al. Renin-angiotensin system inhibition in advanced chronic kidney disease. New England J Med. 2022;387:2021\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2210639.","journal-title":"New England J Med"},{"key":"2916_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13467","author":"YH Chou","year":"2018","unstructured":"Chou YH, Chu TS, Lin SL. Role of renin-angiotensin system in acute kidney injury-chronic kidney disease transition. Nephrology. 2018. https:\/\/doi.org\/10.1111\/nep.13467.","journal-title":"Nephrology"},{"key":"2916_CR9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: A bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis Official J Nat Kidney Found. 2016;67:728\u201341. https:\/\/doi.org\/10.1053\/j.ajkd.2015.10.011.","journal-title":"Am J Kidney Dis Official J Nat Kidney Found"},{"key":"2916_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11906-019-0995-y","volume":"21","author":"R Iturriaga","year":"2019","unstructured":"Iturriaga R, Castillo-Gal\u00e1n S. Potential contribution of carotid body-induced sympathetic and renin-angiotensin system overflow to pulmonary hypertension in intermittent hypoxia. Cur Hypertens Rep. 2019;21:89. https:\/\/doi.org\/10.1007\/s11906-019-0995-y.","journal-title":"Cur Hypertens Rep"},{"key":"2916_CR11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1086\/675984","volume":"4","author":"BA Maron","year":"2014","unstructured":"Maron BA, Leopold JA. The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series). Pulmonary Circ. 2014;4:200\u201310. https:\/\/doi.org\/10.1086\/675984.","journal-title":"Pulmonary Circ"},{"key":"2916_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12931-017-0679-6","volume":"18","author":"M Vaillancourt","year":"2017","unstructured":"Vaillancourt M, et al. Autonomic nervous system involvement in pulmonary arterial hypertension. Respir Res. 2017;18:201. https:\/\/doi.org\/10.1186\/s12931-017-0679-6.","journal-title":"Respir Res"},{"key":"2916_CR13","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1164\/rccm.201203-0411OC","volume":"186","author":"FS de Man","year":"2012","unstructured":"de Man FS, et al. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186:780\u20139. https:\/\/doi.org\/10.1164\/rccm.201203-0411OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"2916_CR14","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.chest.2020.09.258","volume":"159","author":"T Lahm","year":"2021","unstructured":"Lahm T, et al. Renin-angiotensin-aldosterone system inhibitor use and mortality in pulmonary hypertension: insights from the veterans affairs clinical assessment reporting and tracking database. Chest. 2021;159:1586\u201397. https:\/\/doi.org\/10.1016\/j.chest.2020.09.258.","journal-title":"Chest"},{"key":"2916_CR15","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00515.2016","author":"YX Zhang","year":"2018","unstructured":"Zhang YX, et al. Renin-angiotensin system regulates pulmonary arterial smooth muscle cell migration in chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2018. https:\/\/doi.org\/10.1152\/ajplung.00515.2016.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2916_CR16","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1016\/j.jcin.2022.09.013","volume":"15","author":"H Zhang","year":"2022","unstructured":"Zhang H, et al. Pulmonary artery denervation for pulmonary arterial hypertension: a sham-controlled randomized PADN-CFDA trial. JACC Cardiovasc Int. 2022;15:2412\u201323. https:\/\/doi.org\/10.1016\/j.jcin.2022.09.013.","journal-title":"JACC Cardiovasc Int"},{"key":"2916_CR17","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1681\/ASN.2014050518","volume":"26","author":"W Cao","year":"2015","unstructured":"Cao W, et al. A salt-induced reno-cerebral reflex activates renin-angiotensin systems and promotes CKD progression. J Am Soc Nephrol. 2015;26:1619\u201333. https:\/\/doi.org\/10.1681\/ASN.2014050518.","journal-title":"J Am Soc Nephrol"},{"key":"2916_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41420-022-00931-8","volume":"8","author":"J Wang","year":"2022","unstructured":"Wang J, et al. Ferroptosis, a new target for treatment of renal injury and fibrosis in a 5\/6 nephrectomy-induced CKD rat model. Cell Death Dis. 2022;8:127. https:\/\/doi.org\/10.1038\/s41420-022-00931-8.","journal-title":"Cell Death Dis"},{"key":"2916_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/bph.15285","volume":"178","author":"Q Jiang","year":"2021","unstructured":"Jiang Q, et al. Dysregulation of BMP9\/BMPR2\/SMAD signalling pathway contributes to pulmonary fibrosis and pulmonary hypertension induced by bleomycin in rats. British J Pharmacol. 2021;178:203\u201316. https:\/\/doi.org\/10.1111\/bph.15285.","journal-title":"British J Pharmacol"},{"key":"2916_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/bph.15314","volume":"178","author":"C Zhang","year":"2021","unstructured":"Zhang C, et al. Mitomycin C induces pulmonary vascular endothelial-to-mesenchymal transition and pulmonary veno-occlusive disease via Smad3-dependent pathway in rats. British J Pharmacol. 2021;178:217\u201335. https:\/\/doi.org\/10.1111\/bph.15314.","journal-title":"British J Pharmacol"},{"key":"2916_CR21","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1111\/bph.15000","volume":"177","author":"Y Chen","year":"2020","unstructured":"Chen Y, et al. Tetramethylpyrazine: a promising drug for the treatment of pulmonary hypertension. British J Pharmacol. 2020;177:2743\u201364. https:\/\/doi.org\/10.1111\/bph.15000.","journal-title":"British J Pharmacol"},{"key":"2916_CR22","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/bph.15696","volume":"179","author":"Q Zheng","year":"2022","unstructured":"Zheng Q, et al. Established pulmonary hypertension in rats was reversed by a combination of a HIF-2\u03b1 antagonist and a p53 agonist. British J Pharmacol. 2022;179:1065\u201381. https:\/\/doi.org\/10.1111\/bph.15696.","journal-title":"British J Pharmacol"},{"key":"2916_CR23","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00398.2021","author":"RJ Adam","year":"2022","unstructured":"Adam RJ, Williams AC, Kriegel AJ. Comparison of the surgical resection and infarct 5\/6 nephrectomy rat models of chronic kidney disease. Am J Physiol Renal physiol. 2022. https:\/\/doi.org\/10.1152\/ajprenal.00398.2021.","journal-title":"Am J Physiol Renal physiol"},{"key":"2916_CR24","doi-asserted-by":"publisher","first-page":"35906","DOI":"10.1038\/srep35906","volume":"6","author":"S Jiang","year":"2016","unstructured":"Jiang S, et al. Proteomic and phosphoproteomic analysis of renal cortex in a salt-load rat model of advanced kidney damage. Sci Rep. 2016;6:35906. https:\/\/doi.org\/10.1038\/srep35906.","journal-title":"Sci Rep"},{"key":"2916_CR25","first-page":"104","volume":"57","author":"P Kujal","year":"2008","unstructured":"Kujal P, Vernerov\u00e1 Z. 5\/6 nephrectomy as an experimental model of chronic renal failure and adaptation to reduced nephron number. Cesk Fysiol. 2008;57:104\u20139.","journal-title":"Cesk Fysiol"},{"key":"2916_CR26","doi-asserted-by":"publisher","unstructured":"Diwan V, Brown L, Gobe GC. Adenine-induced chronic kidney disease in rats. Nephrology (Carlton, Vic). 2018;23:5-11. https:\/\/doi.org\/10.1111\/nep.13180","DOI":"10.1111\/nep.13180"},{"key":"2916_CR27","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.3352","volume":"5","author":"Y Tanada","year":"2017","unstructured":"Tanada Y, et al. The metabolic profile of a rat model of chronic kidney disease. PeerJ. 2017;5: e3352. https:\/\/doi.org\/10.7717\/peerj.3352.","journal-title":"PeerJ"},{"key":"2916_CR28","doi-asserted-by":"publisher","unstructured":"Mahmoud MM, Shamseldeen AM, Rashed LA, Fares AE, Shamaa A, Gharib DM. Contribution of volume overload to progression of cardiovascular disease in a rat model of chronic kidney disease. Canad J Physiol Pharmacol 2018;96:1197-1208. https:\/\/doi.org\/10.1139\/cjpp-2018-0070","DOI":"10.1139\/cjpp-2018-0070"},{"key":"2916_CR29","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/circulationaha.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D, B\u00f6hm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143:1157\u201372. https:\/\/doi.org\/10.1161\/circulationaha.120.050686.","journal-title":"Circulation"},{"key":"2916_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/toxins12030161","author":"N Kaesler","year":"2020","unstructured":"Kaesler N, Babler A, Floege J, Kramann R. Cardiac remodeling in chronic kidney disease. Toxins. 2020. https:\/\/doi.org\/10.3390\/toxins12030161.","journal-title":"Toxins"},{"key":"2916_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cardfail.2006.11.005","volume":"13","author":"Y Li","year":"2007","unstructured":"Li Y, et al. Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure. J Cardiac Failure. 2007;13:155\u201362. https:\/\/doi.org\/10.1016\/j.cardfail.2006.11.005.","journal-title":"J Cardiac Failure"},{"key":"2916_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.suppl_1.29","author":"GM London","year":"2002","unstructured":"London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dialysis, Trans Official Publ Euro Dialysis Trans Assoc Euro Renal Assoc. 2002. https:\/\/doi.org\/10.1093\/ndt\/17.suppl_1.29.","journal-title":"Nephrol Dialysis, Trans Official Publ Euro Dialysis Trans Assoc Euro Renal Assoc"},{"key":"2916_CR33","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1038\/labinvest.2012.136","volume":"92","author":"M Ogawa","year":"2012","unstructured":"Ogawa M, et al. Impaired post-infarction cardiac remodeling in chronic kidney disease is due to excessive renin release. Lab Investig J Techn Methods Pathol. 2012;92:1766\u201376. https:\/\/doi.org\/10.1038\/labinvest.2012.136.","journal-title":"Lab Investig J Techn Methods Pathol"},{"key":"2916_CR34","doi-asserted-by":"publisher","first-page":"E136","DOI":"10.1152\/ajpendo.1987.252.1.E136","volume":"252","author":"S Kim","year":"1987","unstructured":"Kim S, Iwao H, Nakamura N, Ikemoto F, Yamamoto K. Fate of circulating renin in conscious rats. Am J Physiol. 1987;252:E136-146. https:\/\/doi.org\/10.1152\/ajpendo.1987.252.1.E136.","journal-title":"Am J Physiol"},{"key":"2916_CR35","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/cphy.c100043","volume":"1","author":"EJ Johns","year":"2011","unstructured":"Johns EJ, Kopp UC, DiBona GF. Neural control of renal function. Compr Physiol. 2011;1:731\u201367. https:\/\/doi.org\/10.1002\/cphy.c100043.","journal-title":"Compr Physiol"},{"key":"2916_CR36","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00021.2022","author":"H Christou","year":"2022","unstructured":"Christou H, Khalil RA. Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies. Am J Physiol Heart Circ Physiol. 2022. https:\/\/doi.org\/10.1152\/ajpheart.00021.2022.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2916_CR37","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00441-016-2539-y","volume":"367","author":"RM Tuder","year":"2017","unstructured":"Tuder RM. Pulmonary vascular remodeling in pulmonary hypertension. Cell Tissue Res. 2017;367:643\u20139. https:\/\/doi.org\/10.1007\/s00441-016-2539-y.","journal-title":"Cell Tissue Res"},{"key":"2916_CR38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.amjmed.2003.09.034","volume":"116","author":"UC Brewster","year":"2004","unstructured":"Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med. 2004;116:263\u201372. https:\/\/doi.org\/10.1016\/j.amjmed.2003.09.034.","journal-title":"Am J Med"},{"key":"2916_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1254\/jphs.12r03cr","volume":"120","author":"PC Santos","year":"2012","unstructured":"Santos PC, Krieger JE, Pereira AC. Renin-angiotensin system, hypertension, and chronic kidney disease: pharmacogenetic implications. J Pharmacol Sci. 2012;120:77\u201388. https:\/\/doi.org\/10.1254\/jphs.12r03cr.","journal-title":"J Pharmacol Sci"},{"key":"2916_CR40","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3904\/kjim.2014.29.3.291","volume":"29","author":"HE Yoon","year":"2014","unstructured":"Yoon HE, Choi BS. The renin-angiotensin system and aging in the kidney. Korean J Int Med. 2014;29:291\u20135. https:\/\/doi.org\/10.3904\/kjim.2014.29.3.291.","journal-title":"Korean J Int Med"},{"key":"2916_CR41","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1001\/archinte.168.8.832","volume":"168","author":"LJ Appel","year":"2008","unstructured":"Appel LJ, et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Archives Int Med. 2008;168:832\u20139. https:\/\/doi.org\/10.1001\/archinte.168.8.832.","journal-title":"Archives Int Med"},{"key":"2916_CR42","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1517\/14656566.2015.1079623","volume":"16","author":"DF M\u00e1rquez","year":"2015","unstructured":"M\u00e1rquez DF, Ruiz-Hurtado G, Ruilope LM, Segura J. An update of the blockade of the renin angiotensin aldosterone system in clinical practice. Expert Opin Pharmacothera. 2015;16:2283\u201392. https:\/\/doi.org\/10.1517\/14656566.2015.1079623.","journal-title":"Expert Opin Pharmacothera"},{"key":"2916_CR43","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00467-007-0737-2","volume":"23","author":"T Nguyen","year":"2008","unstructured":"Nguyen T, Toto RD. Slowing chronic kidney disease progression: results of prospective clinical trials in adults. Pediatric Nephrol. 2008;23:1409\u201322. https:\/\/doi.org\/10.1007\/s00467-007-0737-2.","journal-title":"Pediatric Nephrol"},{"key":"2916_CR44","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s40256-021-00467-9","volume":"21","author":"E Sanidas","year":"2021","unstructured":"Sanidas E, Papadopoulos D, Chatzis M, Velliou M, Barbetseas J. Renin angiotensin aldosterone system inhibitors in chronic kidney disease: a difficult equation. A Journal Cardiovasc Drugs Drugs Devices Other Int. 2021;21:619\u201327. https:\/\/doi.org\/10.1007\/s40256-021-00467-9.","journal-title":"A Journal Cardiovasc Drugs Drugs Devices Other Int"},{"key":"2916_CR45","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1159\/000112269","volume":"28","author":"R Toto","year":"2008","unstructured":"Toto R, Palmer BF. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease. Am J Nephrol. 2008;28:372\u201380. https:\/\/doi.org\/10.1159\/000112269.","journal-title":"Am J Nephrol"},{"key":"2916_CR46","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10557-020-07114-6","volume":"36","author":"F Zhang","year":"2022","unstructured":"Zhang F, et al. Research progress on pulmonary arterial hypertension and the role of the angiotensin converting enzyme 2-angiotensin-(1\u20137)-mas axis in pulmonary arterial hypertension. Cardiovasc Drugs Therapy. 2022;36:363\u201370. https:\/\/doi.org\/10.1007\/s10557-020-07114-6.","journal-title":"Cardiovasc Drugs Therapy"},{"key":"2916_CR47","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00408-013-9470-8","volume":"191","author":"G Li","year":"2013","unstructured":"Li G, et al. ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats. Lung. 2013;191:327\u201336. https:\/\/doi.org\/10.1007\/s00408-013-9470-8.","journal-title":"Lung"},{"key":"2916_CR48","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11010-016-2740-z","volume":"418","author":"E Malikova","year":"2016","unstructured":"Malikova E, et al. Local and systemic renin-angiotensin system participates in cardiopulmonary-renal interactions in monocrotaline-induced pulmonary hypertension in the rat. Mol Cell Biochem. 2016;418:147\u201357. https:\/\/doi.org\/10.1007\/s11010-016-2740-z.","journal-title":"Mol Cell Biochem"},{"key":"2916_CR49","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/ehf2.13225","volume":"8","author":"JS Tran","year":"2021","unstructured":"Tran JS, et al. Acute pulmonary pressure change after transition to sacubitril\/valsartan in patients with heart failure reduced ejection fraction. ESC Heart Failure. 2021;8:1706\u201310. https:\/\/doi.org\/10.1002\/ehf2.13225.","journal-title":"ESC Heart Failure"},{"key":"2916_CR50","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2018","author":"L Mascitelli","year":"2007","unstructured":"Mascitelli L, Pezzetta F. Inhibition of the renin-angiotensin system in patients with COPD and pulmonary hypertension. Chest. 2007. https:\/\/doi.org\/10.1378\/chest.06-2018.","journal-title":"Chest"},{"key":"2916_CR51","first-page":"59","volume":"52","author":"CE Paitl","year":"1989","unstructured":"Paitl CE, et al. Effects of captopril on hemodynamics, gas exchange and exercise capacity in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease. Arq Bras Cardiol. 1989;52:59\u201367.","journal-title":"Arq Bras Cardiol"},{"key":"2916_CR52","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1164\/rccm.200811-1678OC","volume":"179","author":"AJ Ferreira","year":"2009","unstructured":"Ferreira AJ, et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179:1048\u201354. https:\/\/doi.org\/10.1164\/rccm.200811-1678OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"2916_CR53","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s11906-010-0122-6","volume":"12","author":"CN Bradford","year":"2010","unstructured":"Bradford CN, Ely DR, Raizada MK. Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy. Cur Hypertens Rep. 2010;12:212\u20139. https:\/\/doi.org\/10.1007\/s11906-010-0122-6.","journal-title":"Cur Hypertens Rep"},{"key":"2916_CR54","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1161\/circresaha.119.316298","volume":"127","author":"T Xie","year":"2020","unstructured":"Xie T, et al. Erythrocyte metabolic reprogramming by sphingosine 1-phosphate in chronic kidney disease and therapies. Circ Res. 2020;127:360\u201375. https:\/\/doi.org\/10.1161\/circresaha.119.316298.","journal-title":"Circ Res"},{"key":"2916_CR55","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1007\/s00018-019-03155-9","volume":"76","author":"YL Feng","year":"2019","unstructured":"Feng YL, et al. Microbiome-metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease. Cell Mol Life Sci. 2019;76:4961\u201378. https:\/\/doi.org\/10.1007\/s00018-019-03155-9.","journal-title":"Cell Mol Life Sci"},{"key":"2916_CR56","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1136\/gutjnl-2019-319766","volume":"69","author":"X Wang","year":"2020","unstructured":"Wang X, et al. Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents. Gut. 2020;69:2131\u201342. https:\/\/doi.org\/10.1136\/gutjnl-2019-319766.","journal-title":"Gut"},{"key":"2916_CR57","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/ndt\/gfz126","volume":"35","author":"F Nanto-Hara","year":"2020","unstructured":"Nanto-Hara F, et al. The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease. Nephrol Dialysis, Trans Official Publ Euro Dialysis Trans Assoc\u2014Euro Renal Assoc. 2020;35:250\u201364. https:\/\/doi.org\/10.1093\/ndt\/gfz126.","journal-title":"Nephrol Dialysis, Trans Official Publ Euro Dialysis Trans Assoc\u2014Euro Renal Assoc"},{"key":"2916_CR58","doi-asserted-by":"publisher","first-page":"657827","DOI":"10.3389\/fphar.2021.657827","volume":"12","author":"Y Mo","year":"2021","unstructured":"Mo Y, et al. Microbiome-metabolomics analysis reveals the protection mechanism of \u03b1-ketoacid on adenine-induced chronic kidney disease in rats. Front Pharmacol. 2021;12:657827. https:\/\/doi.org\/10.3389\/fphar.2021.657827.","journal-title":"Front Pharmacol"},{"key":"2916_CR59","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133817","author":"KT Bush","year":"2020","unstructured":"Bush KT, Singh P, Nigam SK. Gut-derived uremic toxin handling in vivo requires OAT-mediated tubular secretion in chronic kidney disease. JCI insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.133817.","journal-title":"JCI insight"},{"key":"2916_CR60","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/cphy.c130037","volume":"4","author":"WB Bollag","year":"2014","unstructured":"Bollag WB. Regulation of aldosterone synthesis and secretion. Compr Physiol. 2014;4:1017\u201355. https:\/\/doi.org\/10.1002\/cphy.c130037.","journal-title":"Compr Physiol"},{"key":"2916_CR61","doi-asserted-by":"publisher","first-page":"100191","DOI":"10.1016\/j.jlr.2022.100191","volume":"63","author":"SC Spaulding","year":"2022","unstructured":"Spaulding SC, Bollag WB. The role of lipid second messengers in aldosterone synthesis and secretion. J Lipid Res. 2022;63:100191. https:\/\/doi.org\/10.1016\/j.jlr.2022.100191.","journal-title":"J Lipid Res"},{"key":"2916_CR62","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1152\/physrev.00030.2003","volume":"84","author":"A Sp\u00e4t","year":"2004","unstructured":"Sp\u00e4t A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev. 2004;84:489\u2013539. https:\/\/doi.org\/10.1152\/physrev.00030.2003.","journal-title":"Physiol Rev"},{"key":"2916_CR63","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0303-7207(90)90096-q","volume":"72","author":"R Natarajan","year":"1990","unstructured":"Natarajan R, Dunn WD, Stern N, Nadler J. Key role of diacylglycerol-mediated 12-lipoxygenase product formation in angiotensin II-induced aldosterone synthesis. Mol Cell Endocrinol. 1990;72:73\u201380. https:\/\/doi.org\/10.1016\/0303-7207(90)90096-q.","journal-title":"Mol Cell Endocrinol"},{"key":"2916_CR64","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000504228","volume":"105","author":"Y Wang","year":"2020","unstructured":"Wang Y, et al. Aldosterone contributed to pulmonary arterial hypertension development via stimulating aquaporin expression and pulmonary arterial smooth muscle cells proliferation. Pharmacology. 2020;105:405\u201315. https:\/\/doi.org\/10.1159\/000504228.","journal-title":"Pharmacology"},{"key":"2916_CR65","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.amjcard.2013.04.051","volume":"112","author":"BA Maron","year":"2013","unstructured":"Maron BA, et al. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). Am J Cardiol. 2013;112:720\u20135. https:\/\/doi.org\/10.1016\/j.amjcard.2013.04.051.","journal-title":"Am J Cardiol"},{"key":"2916_CR66","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1161\/circulationaha.112.094722","volume":"126","author":"BA Maron","year":"2012","unstructured":"Maron BA, et al. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation. 2012;126:963\u201374. https:\/\/doi.org\/10.1161\/circulationaha.112.094722.","journal-title":"Circulation"},{"key":"2916_CR67","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/cvr\/cvx198","volume":"114","author":"JM Elinoff","year":"2018","unstructured":"Elinoff JM, et al. Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-\u03baB and AP-1 signalling. Cardiovascular Res. 2018;114:65\u201376. https:\/\/doi.org\/10.1093\/cvr\/cvx198.","journal-title":"Cardiovascular Res"},{"key":"2916_CR68","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1086\/681227","volume":"5","author":"M Talati","year":"2015","unstructured":"Talati M, Hemnes A. Fatty acid metabolism in pulmonary arterial hypertension: role in right ventricular dysfunction and hypertrophy. Pulmonary Circu. 2015;5:269\u201378. https:\/\/doi.org\/10.1086\/681227.","journal-title":"Pulmonary Circu"},{"key":"2916_CR69","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1465-9921-12-20","volume":"12","author":"B Fuchs","year":"2011","unstructured":"Fuchs B, et al. Diacylglycerol regulates acute hypoxic pulmonary vasoconstriction via TRPC6. Res Res. 2011;12:20. https:\/\/doi.org\/10.1186\/1465-9921-12-20.","journal-title":"Res Res"},{"issue":"Suppl 2","key":"2916_CR70","first-page":"S3","volume":"6","author":"TF L\u00fcscher","year":"1992","unstructured":"L\u00fcscher TF, et al. Endothelin-induced vasoconstriction and calcium antagonists. J Hum Hypertens. 1992;6(Suppl 2):S3-8.","journal-title":"J Hum Hypertens"},{"key":"2916_CR71","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1111\/bph.13151","volume":"172","author":"T Maier","year":"2015","unstructured":"Maier T, et al. Discovery and pharmacological characterization of a novel potent inhibitor of diacylglycerol-sensitive TRPC cation channels. British J Pharmacol. 2015;172:3650\u201360. https:\/\/doi.org\/10.1111\/bph.13151.","journal-title":"British J Pharmacol"},{"key":"2916_CR72","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00605.2002","author":"DF Slish","year":"2002","unstructured":"Slish DF, Welsh DG, Brayden JE. Diacylglycerol and protein kinase C activate cation channels involved in myogenic tone. Am J Physiol Heart Circu Physiol. 2002. https:\/\/doi.org\/10.1152\/ajpheart.00605.2002.","journal-title":"Am J Physiol Heart Circu Physiol"},{"key":"2916_CR73","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00324.2016","author":"O Karpi\u0144ska","year":"2017","unstructured":"Karpi\u0144ska O, et al. Activation of CB(1) receptors by 2-arachidonoylglycerol attenuates vasoconstriction induced by U46619 and angiotensin II in human and rat pulmonary arteries. Am J Physiol Reg Int Compa Physiol. 2017. https:\/\/doi.org\/10.1152\/ajpregu.00324.2016.","journal-title":"Am J Physiol Reg Int Compa Physiol"},{"key":"2916_CR74","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00313.2022","author":"T Zhao","year":"2022","unstructured":"Zhao T, et al. Mechanosensitive cation currents through TRPC6 and Piezo1 channels in human pulmonary arterial endothelial cells. Am J Physiol Cell Physiol. 2022. https:\/\/doi.org\/10.1152\/ajpcell.00313.2022.","journal-title":"Am J Physiol Cell Physiol"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02916-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-024-02916-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02916-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T09:10:13Z","timestamp":1722330613000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-024-02916-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2916"],"URL":"https:\/\/doi.org\/10.1186\/s12931-024-02916-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3937248\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.1101\/2024.01.25.577304","asserted-by":"object"}]},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"assertion":[{"value":"7 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments described in this study were conducted in compliance with the guidelines of The First Affiliated Hospital of Guangzhou Medical University Animal Care and Use Committee (Approval number: 2021247).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"288"}}